{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021181","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.878911+00:00","generated_at":"2026-06-15T04:15:00.330216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amylyx Q1 net product revenue $71.4M; net income $1.6M vs $47.8M loss YoY","bullets":["Net product revenue $71.4M from RELYVRIO/ALBRIOZA ALS sales; cost of sales $5.3M.","Net income $1.6M ($0.02/share) vs net loss $47.8M ($0.93/share) in Q1 2022.","Cash and investments $345.7M at March 31, 2023, down slightly from $346.9M at Dec 31, 2022.","Phase 3 PHOENIX ALS trial fully enrolled (664 participants); topline results expected mid-2024.","Plans to initiate global Phase 3 trial of AMX0035 in progressive supranuclear palsy in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021181","json":"https://secwatch.observer/filing/0000950170-23-021181.json","markdown":"https://secwatch.observer/filing/0000950170-23-021181.md","text":"https://secwatch.observer/filing/0000950170-23-021181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023021181/0000950170-23-021181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023021181/amlx-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:15:00.330216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3489ba8e1685fbf76b23b439cbb5d4ffcbc44221","claim":"Amylyx Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: revenue $71.4 million, net income $1.6 million, or $0.02 per share, EPS $0.02 per share.","evidence_excerpt":"in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results ˗ First quarter 2023 product revenue of $71.4 million; commercial launches of RELYVRIO ® in U.S. and ALBRIOZATM in Canada for the treatment of ALS continue to progress ˗ Regulatory review ongoing in the EU ˗ Expansion of pipeline","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023021181/0000950170-23-021181-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$71.4 million"},{"label":"Net income","value":"$1.6 million, or $0.02 per share"},{"label":"EPS","value":"$0.02 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}